A Phase I trial to investigate the pharmacokinetics and ECG effects of single doses of linaprazan glurate administered as oral tablets to healthy participants
This early-stage research is looking at a new medication called linaprazan glurate. The main goal is to understand how the body handles this new drug, specifically how it's absorbed, distributed, processed, and removed. Researchers also want to check if it has any effects on the heart's electrical activity, which is measured using an ECG. This study involves healthy volunteers and is designed to find out if single doses of the medication, given as tablets, are safe and well-tolerated. This information is really important to gather before the medicine can be tested in people who have specific health conditions, like severe gastroesophageal reflux disease (eGERD).
At a glance
What is this study about?
This research is about a new medicine called linaprazan glurate. Think of it as a very early test drive for a new car. Before a new car can be sold to the public, engineers need to test it thoroughly in controlled conditions to see how it runs and if all its parts work safely. In the same way, before a new medicine can be given to patients who are unwell, we need to understand how it behaves in the human body.
This particular study is a 'Phase I' trial. This means it's one of the very first times this medicine is being given to people. The main focus is on safety and understanding. We want to see how the body takes in the medicine, how it spreads around, how it's broken down, and how it leaves the body. This is called 'pharmacokinetics'. We also want to check if it affects the heart's electrical activity, which is measured with a simple test called an ECG.
The reason this matters is that we are trying to find new and better ways to treat conditions like 'Erosive Gastroesophageal Reflux Disease' (eGERD), which is a severe form of heartburn that can damage the food pipe. By understanding how linaprazan glurate works in healthy people first, we can make sure it's safe enough to then study in patients who might benefit from it.
Key takeaways
- This is an early-stage study of a new medicine for severe heartburn.
- It helps us understand how the new medicine works and if it's safe in healthy people.
- Participants will receive a single dose of the new medicine.
- Your heart and other body functions will be carefully monitored.
- Participation helps future patients with eGERD.
- You can always change your mind and stop taking part.
Who may be eligible?
To join this study, you need to be an adult, aged 18 years or older. This study is open to both men and women.
Because this is an early-stage study looking at how a new medicine affects healthy people, there will be other important rules about who can take part. For example, you would need to be generally healthy and not have any serious ongoing medical conditions, especially those affecting your heart, liver, or kidneys. You also wouldn't be able to be on other medications that might interfere with the study drug.
The research team will carry out a full health check to make sure the study is a good and safe fit for you. They will explain all the requirements in detail.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally in good health?
- Do you not have any major ongoing medical conditions?
- Are you willing to avoid other medications during the study period?
- Are you able to attend several clinic visits?
What does participation involve?
If you choose to take part, you would receive a single dose of the study medicine, linaprazan glurate, in tablet form. You would need to visit the study clinic or hospital a few times. During these visits, the research team would closely monitor your health. This would involve taking blood and urine samples, checking your vital signs (like blood pressure and heart rate), and performing regular ECGs to see how the medicine affects your heart.
You would be carefully observed for a period after taking the medicine to ensure your safety and to collect all necessary information. The total amount of time you would need to commit to the study, including screening, dosing, and follow-up, would be fully explained by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedSweden
Common questions
What is eGERD?
eGERD stands for 'Erosive Gastroesophageal Reflux Disease'. It's a severe type of heartburn where stomach acid causes damage and sores in the lining of the food pipe (oesophagus).
What does 'Phase I' mean?
Phase I is the very first stage of testing a new medicine in people. It mainly focuses on checking the medicine's safety, how it moves through the body, and what dose might be suitable, usually in healthy volunteers.
What does an ECG measure?
An ECG (electrocardiogram) is a simple, painless test that records the electrical activity of your heart. It helps doctors check if your heart is working normally.
Will I get the actual medicine or a dummy pill?
In this specific study, all participants will receive the active study medicine, linaprazan glurate. There won't be a dummy pill (placebo) used in this trial.
Will I be paid for taking part?
Often, early-stage studies like this offer some payment or reimbursement for your time and travel. The study team will provide full details if this is the case for this trial.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.